Evaxion A/S (NASDAQ:EVAX) Receives “Buy” Rating from HC Wainwright

Evaxion A/S (NASDAQ:EVAX)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a research note issued on Friday,Benzinga reports. They currently have a $16.00 price target on the stock. HC Wainwright’s price target would suggest a potential upside of 276.47% from the company’s previous close.

Several other analysts also recently commented on the stock. Wall Street Zen downgraded shares of Evaxion A/S from a “buy” rating to a “hold” rating in a research report on Sunday, March 22nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Evaxion A/S in a research report on Friday, January 9th. Maxim Group assumed coverage on shares of Evaxion A/S in a research report on Thursday, February 19th. They set a “buy” rating and a $10.00 price objective for the company. Lake Street Capital reduced their price objective on shares of Evaxion A/S from $11.00 to $9.00 and set a “buy” rating for the company in a research report on Monday, March 9th. Finally, JonesTrading assumed coverage on shares of Evaxion A/S in a research report on Tuesday, March 10th. They set a “buy” rating and a $10.00 price objective for the company. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Evaxion A/S presently has an average rating of “Moderate Buy” and a consensus target price of $11.00.

Evaxion A/S Stock Performance

Shares of EVAX stock opened at $4.25 on Friday. The company has a market cap of $35.45 million, a price-to-earnings ratio of -3.22 and a beta of 0.19. Evaxion A/S has a 52 week low of $1.42 and a 52 week high of $12.15. The company has a quick ratio of 5.85, a current ratio of 5.85 and a debt-to-equity ratio of 0.41. The firm has a 50 day moving average of $3.73 and a 200-day moving average of $4.77.

Hedge Funds Weigh In On Evaxion A/S

A number of large investors have recently modified their holdings of EVAX. Wesbanco Bank Inc. bought a new position in shares of Evaxion A/S in the 4th quarter worth $48,000. Northwestern Mutual Wealth Management Co. bought a new position in Evaxion A/S during the 4th quarter valued at $38,000. Finally, SmartHarvest Portfolios LLC bought a new position in Evaxion A/S during the 4th quarter valued at $72,000. 11.04% of the stock is currently owned by institutional investors.

Evaxion A/S Company Profile

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.